Yazan Abou-Ismail/ LinkedIn
Nov 10, 2026, 14:55
Yazan Abou-Ismail: First FDA-Approved Factor XIa Inhibitor for Stroke Prevention
Yazan Abou-Ismail, Associate Professor of Hematology at the University of Utah, shared a post on LinkedIn:
“An exciting breakthrough in thrombosis prevention!
Factor 11a inhibitors are finally here!
We now have the first ever FDA approved Factor 11a inhibitor.
The FDA just approved asundexian for secondary prevention of non Afib stroke.
Factor 11a inhibition is a brand new mechanism of anticoagulation and major milestone in the #coagulation world.
In the phase III Oceanic Stroke trial, asundexian reduced the relative risk of ischemic stroke by 26 percent when added to antiplatelet therapy, without a statistically significant increase in overall major bleeding.”
Stay updated with Hemostasis Today.
-
Nov 10, 2026, 14:49Ifeanyichukwu Ifechidere: The Role of Coagulation in Anaesthesia and Surgery
-
Nov 10, 2026, 14:37Salih Ehsan: Common Causes of Microcytic Anemia
-
Nov 10, 2026, 14:28Beyond Platelet Aggregation: Targeting Mitochondrial Pore Opening to Prevent Thrombosis
-
Nov 10, 2026, 14:13Shayan Mohammadmoradi: Jay D. Coffman Award for Emerging Vascular Researcher
-
Nov 10, 2026, 14:10Phil Choi: New Guidance Aims to Improve Care for Patients With AIHA
-
Nov 10, 2026, 13:55Marilena Vrana: Building Momentum for the Future of Plasma-Derived Therapies
-
Nov 10, 2026, 13:32Maya Bishop: Scientific Exchange and Global Connections at AHA 2026
-
Nov 10, 2026, 13:10Alan Nurden։ How Aberrant Splicing Disrupts Megakaryocyte Development in TAR Syndrome
-
Nov 10, 2026, 13:10Masanori Aikawa: NEK7 Research Earns Top Honors at AHA 2026